Skip to content
Screener

UroGen Pharma URGN Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$27.5MMiss by $12.7M
EPS-$0.69Beat by $0.03
Revenue estimate$40.1M
EPS estimate-$0.72

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$90.6M
EPS estimate$0.10

Financials

Q3 2025

Income statement

See full
Revenue$27.5M+9.0%
Net income-$33.3M-40.9%

Balance sheet

See full
Cash & equivalents$90.0M-27.9%
Total debt$129.9M+5.9%
Total equity-$115.4M-552%
Total assets$185.0M-38.7%

Cash flow

See full
Operating cash flow-$42.3M-52.8%
CapEx$87.0K-9.4%
Free cash flow-$42.4M-52.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$922.97M+76.5%
Enterprise value$962.87M+84.9%
P/S9.6×+3.7×

Profitability

See full
Net margin-170.6%+80.7pp
FCF margin-143.1%+69.5pp

Returns & leverage

See full
Current ratio4×-5.0×

Segments

By product

See full
Jelmyto$25.7M+2.0%

FAQ

When did UroGen Pharma report Q3 2025 earnings?
UroGen Pharma (URGN) reported Q3 2025 earnings on November 6, 2025 before market open.
What were UroGen Pharma's Q3 2025 revenue and EPS?
UroGen Pharma reported revenue of $27.5M and eps of $-0.69 for Q3 2025.
Did UroGen Pharma beat estimates in Q3 2025?
Revenue missed the consensus estimate of $40.1M by $12.7M. EPS beat the consensus estimate of $-0.72 by $0.03.
How did UroGen Pharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.0% from $25.2M a year earlier and eps declined 25.5% from $-0.55.
Where can I find UroGen Pharma's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-033466) and the 10-Q periodic report (0001437749-25-033468) directly on SEC EDGAR. The filing index links above go to sec.gov.